AbbVie Inc. Gross Profit
AbbVie Inc. (ABBV) reported Gross Profit of $12.07 billion for the 3-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Income Statement
us-gaap:GrossProfit · last filed 2026-02-20
- AbbVie Inc. gross profit for the quarter ending 2025-12-31 was $12.07B, a 12.70% increase year-over-year.
- AbbVie Inc. gross profit for the quarter ending 2024-12-31 was $10.71B, a 24.53% increase year-over-year.
- AbbVie Inc. gross profit for the quarter ending 2023-12-31 was $8.60B, a 21.50% decline year-over-year.
- AbbVie Inc. gross profit for the quarter ending 2022-12-31 was $10.95B, a 3.64% increase year-over-year.
| Period end | Gross Profit 3 month | Gross Profit 3 month as first filed | Gross Profit 6 month | Gross Profit 9 month | Gross Profit 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $12.07B 10-K · filed 2026-02-20 | ||||
| 2024-12-31 | $10.71B 10-K · filed 2025-02-14 | ||||
| 2023-12-31 | $8.60B 10-K · filed 2024-02-20 | ||||
| 2022-12-31 | $10.95B 10-K · filed 2023-02-17 | ||||
| 2021-12-31 | $10.57B 10-K · filed 2022-02-18 | ||||
| 2020-12-31 | $9.17B 10-K · filed 2021-02-19 | ||||
| 2019-12-31 | $6.70B 10-K · filed 2020-02-21 | $13.26B derived: sum of 2 quarters · filed 2020-02-21 | $19.69B derived: sum of 3 quarters · filed 2020-02-21 | $25.83B derived: sum of 4 quarters · filed 2020-02-21 | |
| 2019-09-30 | $6.56B 10-K · filed 2020-02-21 | $12.99B derived: sum of 2 quarters · filed 2020-02-21 | $19.13B derived: sum of 3 quarters · filed 2020-02-21 | $25.41B derived: sum of 4 quarters · filed 2020-02-21 | |
| 2019-06-30 | $6.44B 10-K · filed 2020-02-21 | $12.57B derived: sum of 2 quarters · filed 2020-02-21 | $18.85B derived: sum of 3 quarters · filed 2020-02-21 | $25.25B derived: sum of 4 quarters · filed 2020-02-21 | |
| 2019-03-31 | $6.13B 10-K · filed 2020-02-21 | $12.42B derived: sum of 2 quarters · filed 2020-02-21 | $18.82B derived: sum of 3 quarters · filed 2020-02-21 | $25.16B derived: sum of 4 quarters · filed 2020-02-21 | |
| 2018-12-31 | $6.28B 10-K · filed 2020-02-21 | $12.68B derived: sum of 2 quarters · filed 2020-02-21 | $19.03B derived: sum of 3 quarters · filed 2020-02-21 | $25.04B derived: sum of 4 quarters · filed 2020-02-21 | |
| 2018-09-30 | $6.40B 10-K · filed 2020-02-21 | $12.74B derived: sum of 2 quarters · filed 2020-02-21 | $18.75B derived: sum of 3 quarters · filed 2020-02-21 | $24.21B derived: sum of 4 quarters · filed 2020-02-21 | |
| 2018-06-30 | $6.34B 10-K · filed 2020-02-21 | $12.35B derived: sum of 2 quarters · filed 2020-02-21 | $17.81B derived: sum of 3 quarters · filed 2020-02-21 | $23.19B derived: sum of 4 quarters · filed 2020-02-21 | |
| 2018-03-31 | $6.01B 10-K · filed 2020-02-21 | $11.46B derived: sum of 2 quarters · filed 2020-02-21 | $16.84B derived: sum of 3 quarters · filed 2020-02-21 | $22.26B derived: sum of 4 quarters · filed 2020-02-21 | |
| 2017-12-31 | $5.46B 10-K · filed 2019-02-27 | $5.46B 10-K · filed 2018-02-16 | $10.84B derived: sum of 2 quarters · filed 2019-02-27 | $16.25B derived: sum of 3 quarters · filed 2019-02-27 | $21.17B derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-09-30 | $5.38B 10-K · filed 2019-02-27 | $10.79B derived: sum of 2 quarters · filed 2019-02-27 | $15.72B derived: sum of 3 quarters · filed 2019-02-27 | $20.96B derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-06-30 | $5.42B 10-K · filed 2019-02-27 | $5.42B 10-K · filed 2018-02-16 | $10.34B derived: sum of 2 quarters · filed 2019-02-27 | $15.58B derived: sum of 3 quarters · filed 2019-02-27 | $20.51B derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | $4.92B 10-K · filed 2019-02-27 | $10.16B derived: sum of 2 quarters · filed 2019-02-27 | $15.09B derived: sum of 3 quarters · filed 2019-02-27 | $20.14B derived: sum of 4 quarters · filed 2019-02-27 | |
| 2016-12-31 | $5.24B 10-K · filed 2018-02-16 | $10.17B derived: sum of 2 quarters · filed 2018-02-16 | $15.22B derived: sum of 3 quarters · filed 2018-02-16 | $19.80B derived: sum of 4 quarters · filed 2018-02-16 | |
| 2016-09-30 | $4.93B 10-K · filed 2018-02-16 | $9.97B derived: sum of 2 quarters · filed 2018-02-16 | $14.56B derived: sum of 3 quarters · filed 2018-02-16 | $19.49B derived: sum of 4 quarters · filed 2018-02-16 | |
| 2016-06-30 | $5.05B 10-K · filed 2018-02-16 | $9.64B derived: sum of 2 quarters · filed 2018-02-16 | $14.56B derived: sum of 3 quarters · filed 2018-02-16 | $19.34B derived: sum of 4 quarters · filed 2018-02-16 | |
| 2016-03-31 | $4.59B 10-K · filed 2018-02-16 | $9.51B derived: sum of 2 quarters · filed 2018-02-16 | $14.29B derived: sum of 3 quarters · filed 2018-02-16 | $18.85B derived: sum of 4 quarters · filed 2018-02-16 | |
| 2015-12-31 | $4.92B 10-K · filed 2017-02-17 | $9.70B derived: sum of 2 quarters · filed 2017-02-17 | $14.26B derived: sum of 3 quarters · filed 2017-02-17 | $18.36B derived: sum of 4 quarters · filed 2017-02-17 | |
| 2015-09-30 | $4.78B 10-K · filed 2017-02-17 | $9.34B derived: sum of 2 quarters · filed 2017-02-17 | $13.43B derived: sum of 3 quarters · filed 2017-02-17 | $17.77B derived: sum of 4 quarters · filed 2017-02-17 | |
| 2015-06-30 | $4.56B 10-K · filed 2017-02-17 | $8.66B derived: sum of 2 quarters · filed 2017-02-17 | $12.99B derived: sum of 3 quarters · filed 2017-02-17 | $16.91B derived: sum of 4 quarters · filed 2017-02-17 | |
| 2015-03-31 | $4.10B 10-K · filed 2017-02-17 | $8.43B derived: sum of 2 quarters · filed 2017-02-17 | $12.36B derived: sum of 3 quarters · filed 2017-02-17 | $16.17B derived: sum of 4 quarters · filed 2017-02-17 | |
| 2014-12-31 | $4.33B 10-K · filed 2016-02-19 | $8.26B derived: sum of 2 quarters · filed 2016-02-19 | $12.07B derived: sum of 3 quarters · filed 2016-02-19 | $15.53B derived: sum of 4 quarters · filed 2016-02-19 | |
| 2014-09-30 | $3.92B 10-K · filed 2016-02-19 | $7.74B derived: sum of 2 quarters · filed 2016-02-19 | $11.20B derived: sum of 3 quarters · filed 2016-02-19 | $15.03B derived: sum of 4 quarters · filed 2016-02-19 | |
| 2014-06-30 | $3.81B 10-K · filed 2016-02-19 | $7.28B derived: sum of 2 quarters · filed 2016-02-19 | $11.11B derived: sum of 3 quarters · filed 2016-02-19 | $14.67B derived: sum of 4 quarters · filed 2016-02-19 | |
| 2014-03-31 | $3.46B 10-K · filed 2016-02-19 | $7.29B derived: sum of 2 quarters · filed 2016-02-19 | $10.86B derived: sum of 3 quarters · filed 2016-02-19 | $14.50B derived: sum of 4 quarters · filed 2016-02-19 | |
| 2013-12-31 | $3.83B 10-K · filed 2015-02-20 | $7.39B derived: sum of 2 quarters · filed 2015-02-20 | $11.03B derived: sum of 3 quarters · filed 2015-02-20 | $14.21B derived: sum of 4 quarters · filed 2015-02-20 | |
| 2013-09-30 | $3.57B 10-K · filed 2015-02-20 | $7.20B derived: sum of 2 quarters · filed 2015-02-20 | $10.38B derived: sum of 3 quarters · filed 2015-02-20 | $14.32B derived: sum of 4 quarters · filed 2015-02-20 | |
| 2013-06-30 | $3.64B 10-K · filed 2015-02-20 | $6.81B derived: sum of 2 quarters · filed 2015-02-20 | $10.76B derived: sum of 3 quarters · filed 2015-02-20 | $14.25B derived: sum of 4 quarters · filed 2015-02-20 | |
| 2013-03-31 | $3.18B 10-K · filed 2015-02-20 | $7.12B derived: sum of 2 quarters · filed 2015-02-20 | $10.61B derived: sum of 3 quarters · filed 2015-02-20 | $14.03B derived: sum of 4 quarters · filed 2015-02-20 | |
| 2012-12-31 | $3.94B 10-K · filed 2014-02-21 | $7.43B derived: sum of 2 quarters · filed 2014-02-21 | $10.86B derived: sum of 3 quarters · filed 2014-02-21 | $13.87B derived: sum of 4 quarters · filed 2014-02-21 | |
| 2012-09-30 | $3.49B 10-K · filed 2014-02-21 | $6.91B derived: sum of 2 quarters · filed 2014-02-21 | $9.93B derived: sum of 3 quarters · filed 2014-02-21 | ||
| 2012-06-30 | $3.42B 10-K · filed 2014-02-21 | $6.44B derived: sum of 2 quarters · filed 2014-02-21 | |||
| 2012-03-31 | $3.02B 10-K · filed 2014-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |